Henk Schuring is the Chief Regulatory and Commercialization Officer at Prilenia. In this position, Henk plays a critical role in defining the regulatory pathway for marketing authorization development and clinical programs and supports the company as it advances toward commercialization. Henk oversees all regulatory and commercialization aspects surrounding the upcoming late-stage clinical studies in Huntington’s disease and ALS. Henk is also responsible for global launch readiness activities.

Henk is a pharmacist with more than 25 years of experience in the pharmaceutical industry for both medicinal products and medicinal devices. He is an experienced executive and has a proven track record as a results-oriented rare disease leader and a creative strategic thinker. Henk has been working in the industry at various positions in quality assurance (QR), regulatory affairs (RA), and commercial at both the European and global levels.

Henk started in the pharmaceutical industry at NPBI (now Fresenius Medical Care) in QA & RA of sterile manufacturing hospital solutions and anything needed for blood banks. From 1995-April 1999, Henk was a consultant in the field of RA and QA. In April 1999, Henk joined Genzyme in regulatory affairs. His last position was Head of Regulatory Strategy for EMEA (Europe, Middle East, Africa) and JAPAC (Japan and Asia-Pacific). In this role, Henk was part of development and commercialization of various rare disease products for Genzyme and Sanofi Genzyme. Many of these products were first approvals of a first treatment for a rare disease.

In November 2014, Henk became VP-Head Rare Neurology at Sanofi Genzyme and was responsible for the area of rare neurology, which was built around the Pompe disease franchise. In February 2017, he began leading the Rare Nephrology and Fabry disease franchise as Global Head of Rare Nephrological Diseases. In these roles, he was responsible for driving the growth and expansion of Sanofi Genzyme’s presence in the therapeutic area. This role oversaw the global marketing and commercial support for products approved in development in close collaboration with various countries. In addition, this role was charged with influencing the direction of science and business development for diseases in the therapeutic area to ensure long-term sustainability.

Henk graduated as a PharmD from the University of Groningen (Netherlands).

• 

  Chief Regulatory and Commercialization Officer in Prilenia

  Pursuing Hope. Leading With Science.